Interleukin Inhibitor (Biologic)Conditionally Approved4h wait period

Dupilumab

Brand names: Dupixent|Last verified: 2026-09-12

FAA Pathway: Conditionally acceptable depending on the underlying condition — 2-week ground trial, 4-hour no-fly after each dose

The FAA lists dupilumab (Dupixent) as a conditionally acceptable medication when used alone, as long as the underlying condition qualifies for certification — your diagnosis is what determines eligibility. You must complete a 2-week ground trial when starting and not fly for 4 hours after each dose. FDA-approved biosimilars are also acceptable, and switching between biologics for the same condition requires a 48-hour ground trial.

Check your medications

Look up any medication in our FAA compatibility database.

Medication Checker

Pilot Tip

Always report all medications on your FAA medical application (Form 8500-8, Item 17a), even OTC medications. Failure to disclose is a far bigger issue than the medication itself.

Certification Details

FAA Status
Conditionally acceptable — depends on the underlying condition (FAA Biologics guidance, updated 08/26/2026)
Ground Trial
2 weeks when starting
Wait Period
4 hours after each dose
Switching
48-hour ground trial when changing to another biologic or biosimilar for the same condition
Underlying Condition
Determines eligibility — see the FAA guidance for your diagnosis

Sources

  • FAA AME Guide — Pharmaceuticals: Biologics, Biosimilars, Non-Biologics (faa.gov/ame_guide/media/Biologics_Biosimilars_Non-Biologics.pdf)

Last verified: 2026-09-12

Frequently Asked Questions

Is Dupilumab allowed for pilots?

The FAA considers Dupilumab (Dupixent) to be "Conditionally Approved" for medical certification purposes. The FAA lists dupilumab (Dupixent) as a conditionally acceptable medication when used alone, as long as the underlying condition qualifies for certification — your diagnosis is what determines eligibility. You must complete a 2-week ground trial when starting and not fly for 4 hours after each dose. FDA-approved biosimilars are also acceptable, and switching between biologics for the same condition requires a 48-hour ground trial.

What is the FAA status of Dupilumab?

Dupilumab has a status of "Conditionally Approved" under FAA medical certification policy. The certification pathway is: Conditionally acceptable depending on the underlying condition — 2-week ground trial, 4-hour no-fly after each dose.

Can I fly while taking Dupilumab?

Flying while taking Dupilumab may be possible through the FAA's Special Issuance process. You will need to meet specific requirements and obtain approval before exercising pilot privileges. Consult an experienced AME for guidance.

Important Notice

The FAA does not publish a comprehensive list of “approved” medications. The information on this page represents our interpretation of publicly available FAA guidance and is provided for informational and educational purposes only. It does not constitute medical advice, legal advice, or a guarantee of certification outcome.

The primary issue with the FAA is always whether the underlying medical condition — not just the medication — is compatible with safe flight. You should only start, stop, or change medications after consulting your treating physician. Always consult with a qualified Aviation Medical Examiner (AME) for guidance specific to your situation. FAA policies are subject to change. ClearedMed is not affiliated with or endorsed by the FAA.